ENTPD1 and melanoma: We have shown that genetic ablation or pharmacological targeting of CD39, i.e., by blocking the conversion of eATP into adenosine, inhibits the growth of melanoma metastases (34), whereas overexpression of CD39 accelerates the growth of colon cancer in experimental models (35).